TARO - Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18 revenue of $130.5M misses by $30.52M
- Taro Pharmaceutical press release ( NYSE: TARO ): FQ2 Non-GAAP EPS of $0.66 misses by $0.18 .
- Revenue of $130.5M (-11.3% Y/Y) misses by $30.52M .
- Gross profit of $47.0M (36.0% of net sales) compared to $62.0M (47.0% of net sales).
- As of September 30, 2022, cash and cash equivalents, short-term bank deposits and marketable securities (both short- and long-term) decreased $58.9M to $1.2B from March 31, 2022.
For further details see:
Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M